FDA Approval of Ekterly Boosts DRI Healthcare’s Portfolio

DRI Healthcare ( ($TSE:DHT.UN) ) has issued an announcement.

DRI Healthcare announced that the FDA has approved Ekterly, developed by KalVista Pharmaceuticals, as the first oral on-demand therapy for hereditary angioedema (HAE). This approval entitles DRI Healthcare to a tiered royalty on Ekterly’s global sales, enhancing its portfolio value. KalVista has opted for additional funding, increasing DRI’s investment to $127 million, and the transaction includes potential milestone payments based on sales performance.

The most recent analyst rating on ($TSE:DHT.UN) stock is a Buy with a C$16.00 price target. To see the full list of analyst forecasts on DRI Healthcare stock, see the TSE:DHT.UN Stock Forecast page.

Spark’s Take on TSE:DHT.UN Stock

According to Spark, TipRanks’ AI Analyst, TSE:DHT.UN is a Neutral.

DRI Healthcare Trust’s strong balance sheet and effective cash flow management are overshadowed by profitability challenges due to revenue decline and net losses. Technical analysis shows a bearish trend, and valuation concerns arise from negative earnings. However, recent corporate events indicate a positive outlook with improved financial results and strategic management, providing a moderate boost to the overall score.

To see Spark’s full report on TSE:DHT.UN stock, click here.

More about DRI Healthcare

DRI Healthcare is a leader in global pharmaceutical royalty monetization, having invested over $3.0 billion since its inception in 1989. The company has acquired more than 75 royalties on over 45 drugs, including notable names like Ekterly, Eylea, Keytruda, and others. DRI Healthcare’s units are traded on the Toronto Stock Exchange under the symbols ‘DHT.UN’ and ‘DHT.U’.

Average Trading Volume: 51,351

Technical Sentiment Signal: Strong Buy

Current Market Cap: C$773.2M

For detailed information about DHT.UN stock, go to TipRanks’ Stock Analysis page.